Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 139

1.

Dyslipidemia among perinatally HIV-infected children enrolled in the PACTS-HOPE cohort, 1999-2004: a longitudinal analysis.

Carter RJ, Wiener J, Abrams EJ, Farley J, Nesheim S, Palumbo P, Bulterys M; Perinatal AIDS Collaborative Transmission Study-HIV Follow-up after Perinatal Exposure (PACTS-HOPE) Group.

J Acquir Immune Defic Syndr. 2006 Apr 1;41(4):453-60.

PMID:
16652053
[PubMed - indexed for MEDLINE]
2.

Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study.

Tsiodras S, Mantzoros C, Hammer S, Samore M.

Arch Intern Med. 2000 Jul 10;160(13):2050-6.

PMID:
10888979
[PubMed - indexed for MEDLINE]
3.

Marked dyslipidemia in human immunodeficiency virus-infected children on protease inhibitor-containing antiretroviral therapy.

Lainka E, Oezbek S, Falck M, Ndagijimana J, Niehues T.

Pediatrics. 2002 Nov;110(5):e56.

PMID:
12415062
[PubMed - indexed for MEDLINE]
4.

Natural history of lipid abnormalities and fat redistribution among human immunodeficiency virus-infected children receiving long-term, protease inhibitor-containing, highly active antiretroviral therapy regimens.

Taylor P, Worrell C, Steinberg SM, Hazra R, Jankelevich S, Wood LV, Zwerski S, Yarchoan R, Zeichner S.

Pediatrics. 2004 Aug;114(2):e235-42.

PMID:
15286262
[PubMed - indexed for MEDLINE]
5.

Prevalence of elevated cholesterol and associated risk factors among perinatally HIV-infected children (4-19 years old) in Pediatric AIDS Clinical Trials Group 219C.

Farley J, Gona P, Crain M, Cervia J, Oleske J, Seage G, Lindsey J; Pediatric AIDS Clinical Trials Group Study 219C Team.

J Acquir Immune Defic Syndr. 2005 Apr 1;38(4):480-7.

PMID:
15764965
[PubMed - indexed for MEDLINE]
6.

Long-term safety and effectiveness of ritonavir, nelfinavir, and lopinavir/ritonavir in antiretroviral-experienced HIV-infected children.

Rudin C, Burri M, Shen Y, Rode R, Nadal D; Pediatric Infectious Disease Group of Switzerland; Swiss Mother and Child HIV Cohort Study (MoCHiV).

Pediatr Infect Dis J. 2008 May;27(5):431-7. doi: 10.1097/INF.0b013e3181646d5a.

PMID:
18382386
[PubMed - indexed for MEDLINE]
7.

Lipodystrophy in HIV-infected pediatric patients receiving protease inhibitors.

Temple ME, Koranyi KI, Nahata MC.

Ann Pharmacother. 2003 Sep;37(9):1214-8.

PMID:
12921501
[PubMed - indexed for MEDLINE]
8.

Lipodystrophy syndrome in human immunodeficiency virus-infected children.

Amaya RA, Kozinetz CA, McMeans A, Schwarzwald H, Kline MW.

Pediatr Infect Dis J. 2002 May;21(5):405-10.

PMID:
12150177
[PubMed - indexed for MEDLINE]
9.

Impact of protease inhibitor-containing combination antiretroviral therapies on height and weight growth in HIV-infected children.

Buchacz K, Cervia JS, Lindsey JC, Hughes MD, Seage GR 3rd, Dankner WM, Oleske JM, Moye J.

Pediatrics. 2001 Oct;108(4):E72.

PMID:
11581480
[PubMed - indexed for MEDLINE]
10.

Improvement in insulin sensitivity and dyslipidemia in protease inhibitor-treated adult male patients after switch to atazanavir/ritonavir.

Busti AJ, Bedimo R, Margolis DM, Hardin DS.

J Investig Med. 2008 Feb;56(2):539-44. doi: 10.231/JIM.0b013e3181641b26.

PMID:
18317438
[PubMed - indexed for MEDLINE]
11.

Hypertriglyceridemia and hypercholesterolemia in human immunodeficiency virus-1-infected children treated with protease inhibitors.

Solórzano Santos F, Gochicoa Rangel LG, Palacios Saucedo G, Vázquez Rosales G, Miranda Novales MG.

Arch Med Res. 2006 Jan;37(1):129-32.

PMID:
16314198
[PubMed - indexed for MEDLINE]
12.

Effect of highly active antiretroviral therapy (HAART) and hepatitis C Co-infection on hyperlipidemia in HIV-infected patients: a retrospective longitudinal study.

Patroni A, Torti C, Tomasoni L, Quiros Roldan E, Bertelli D, Puoti M, Cadeo GP, Sleiman I, Tinelli C, Carosi G, Castelli F.

HIV Clin Trials. 2002 Nov-Dec;3(6):451-61.

PMID:
12501128
[PubMed - indexed for MEDLINE]
13.

Association of hypercholesterolemia incidence with antiretroviral treatment, including protease inhibitors, among perinatally HIV-infected children.

Tassiopoulos K, Williams PL, Seage GR 3rd, Crain M, Oleske J, Farley J; International Maternal Pediatric Adolescent AIDS Clinical Trials 219C Team.

J Acquir Immune Defic Syndr. 2008 Apr 15;47(5):607-14. doi: 10.1097/QAI.0b013e3181648e16.

PMID:
18209684
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Long-term evaluation of glucose homeostasis in a cohort of HAART-treated HIV-infected children: a longitudinal, observational cohort study.

Viganò A, Brambilla P, Pattarino G, Stucchi S, Fasan S, Raimondi C, Cerini C, Giacomet V, Zuccotti GV, Bedogni G.

Clin Drug Investig. 2009;29(2):101-9. doi: 10.2165/0044011-200929020-00004.

PMID:
19133705
[PubMed - indexed for MEDLINE]
15.

Dyslipidemia in a cohort of HIV-infected Latin American children receiving highly active antiretroviral therapy.

Brewinski M, Megazzini K, Hance LF, Cruz MC, Pavia-Ruz N, Della Negra M, Ferreira FG, Marques H, Hazra R; NISDI Pediatric Study Group 2010.

J Trop Pediatr. 2011 Oct;57(5):324-32. doi: 10.1093/tropej/fmq089. Epub 2010 Oct 1.

PMID:
20889625
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

High-density lipoprotein cholesterol in HIV-infected patients: evidence for an association with HIV-1 viral load, antiretroviral therapy status, and regimen composition.

Bernal E, Masiá M, Padilla S, Gutiérrez F.

AIDS Patient Care STDS. 2008 Jul;22(7):569-75. doi: 10.1089/apc.2007.0186.

PMID:
18479224
[PubMed - indexed for MEDLINE]
17.

Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.

Nguyen ST, Eaton SA, Bain AM, Rahman AP, Payne KD, Bedimo R, Herrington JD, Maclayton DO, Rodriguez-Barradas MC, Busti AJ.

Pharmacotherapy. 2008 Mar;28(3):323-30. doi: 10.1592/phco.28.3.323.

PMID:
18294112
[PubMed - indexed for MEDLINE]
18.

Successful simplification of protease inhibitor-based HAART with triple nucleoside regimens in children vertically infected with HIV.

Palma P, Romiti ML, Cancrini C, Pensieroso S, Montesano C, Santucci MB, Bernardi S, Martino AM, Rossi P, Castelli-Gattinara G.

AIDS. 2007 Nov 30;21(18):2465-72.

PMID:
18025883
[PubMed - indexed for MEDLINE]
19.

Predictive factors of virological success to salvage regimens containing protease inhibitors in HIV-1 infected children.

Larru B, de Mendoza C, Bellón JM, de José MI, Mellado MJ, Soriano V, Muñoz-Fernandez MA, Ramos JT.

BMC Infect Dis. 2007 Jun 10;7:55.

PMID:
17559687
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results.

Gatell J, Salmon-Ceron D, Lazzarin A, Van Wijngaerden E, Antunes F, Leen C, Horban A, Wirtz V, Odeshoo L, Van den Dungen M, Gruber C, Ledesma E; SWAN Study Group.

Clin Infect Dis. 2007 Jun 1;44(11):1484-92. Epub 2007 Apr 25.

PMID:
17479947
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk